NCT05286320View on ClinicalTrials.gov

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Unresectable Hepatocellular CarcinomaPembrolizumabLenvatinibStereotactic Body Radiotherapy
Interventions
DRUG

Lenvatinib/Pembrolizumab plus SBRT combinations

Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT05286320 - Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | Biotech Hunter | Biotech Hunter